Intrepid Family Office LLC Has $929,000 Stock Holdings in Natera, Inc. $NTRA

Intrepid Family Office LLC lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 35.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,500 shares of the medical research company’s stock after selling 3,000 shares during the period. Natera comprises about 0.8% of Intrepid Family Office LLC’s investment portfolio, making the stock its 25th biggest holding. Intrepid Family Office LLC’s holdings in Natera were worth $929,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after acquiring an additional 106 shares in the last quarter. Hilltop National Bank acquired a new position in Natera in the 2nd quarter worth about $33,000. Oliver Lagore Vanvalin Investment Group acquired a new position in Natera in the 2nd quarter worth about $36,000. Summit Securities Group LLC purchased a new stake in shares of Natera during the 1st quarter worth about $39,000. Finally, AlphaQuest LLC lifted its holdings in shares of Natera by 1,857.1% during the 1st quarter. AlphaQuest LLC now owns 274 shares of the medical research company’s stock valued at $39,000 after buying an additional 260 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of research reports. UBS Group increased their price objective on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. BTIG Research boosted their target price on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday. JPMorgan Chase & Co. raised their price target on shares of Natera from $240.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, November 25th. Barclays lifted their price objective on shares of Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Evercore ISI increased their target price on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Fifteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $225.29.

Natera Price Performance

Natera stock opened at $239.14 on Tuesday. The firm has a market cap of $33.00 billion, a price-to-earnings ratio of -104.43 and a beta of 1.63. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $246.90. The firm has a fifty day moving average price of $201.07 and a two-hundred day moving average price of $174.58.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Roelof Botha sold 75,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $236.12, for a total value of $17,709,000.00. Following the completion of the sale, the director directly owned 1,154,198 shares of the company’s stock, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Roy D. Baynes sold 7,668 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $223.08, for a total transaction of $1,710,577.44. Following the completion of the sale, the director owned 18,359 shares in the company, valued at $4,095,525.72. This represents a 29.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 307,687 shares of company stock valued at $63,466,360. Corporate insiders own 5.63% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.